Loading
Cardinal Health Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 08 Aug 2023.
Cardinal Health Inc: what insiders have been doing
Every trade that managers of Cardinal Health Inc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Dublin, United States. It was founded in 1971. In the past year (18 October 2025 to 18 October 2026), 84 filings came from 28 insiders.
No insider bought on the market over the period, while 8 insiders filed 33 sales totalling €52.2M. At €6.1M, the sale published on 20 August 2026 by Hollar Jason M. is the largest of the period (0.014% of market cap).
Compared with its exchange (5,458 companies, median 22 filings), a count of 84 filings is above the norm. The full history, which starts in 2021, counts 3 purchases against 42 sales. The 10-K for the year ended 30 June 2026 shows 254.25 bn USD of revenue and 1.71 bn USD of net income and a dividend of 2.04 USD per share.
Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
265
Thresholds
n/a
Buy Volume
€28,928
3 ops. · all time
Sell Volume
€67M
42 ops. · all time
Who traded when
BuySaleJason M. Hollar11 sales
Aaron E. Alt6 sales
Michelle D. Greene5 sales
Deborah Weitzman4 sales
Jessica L. Mayer4 sales
Stephen M. Mason4 sales
+2 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Cardinal Health Inc Buy (bullish), based on 15 analysts. Average price target: US$270.47.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 17,242 of 24,148 companies
37.3
score / 100
Value50
Quality25
FCF yld7.7%
Earn yld2.9%
EV/EBITDA19.4x
ROE·
Gross mgn3.8%
Net mgn0.7%
Debt/EBITDA2.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
US$253.71
Analyst consensus
15 analystsBuy
US$235.00Target US$270.47(+7%)US$292.00
Income statement
RevenueUS$254.2B
Gross profitUS$9.8B4% margin
EBITDAUS$3.5B1% margin
Net incomeUS$1.7B0.7% margin
Valuation
PER (trailing)34.0x
PER (forward)18.0x
Beta0.50
Balance sheet & cash
Market capUS$58.7B
Total debtUS$8.9B
Free Cash FlowUS$4.5B
Profitability & ownership
ROA3.7%
% insiders0.3%
% institutions91.5%
Last declaration on 20 August 2026
Declarations265 total
686 shares@ US$237.250.0003% mcap3.2% of flowCommon SharesSEC:0001945228-26-000005:3
100 shares@ US$237.400.0000% mcap2.4% of flowCommon SharesSEC:0001945352-26-000003:0
12,972 shares@ US$237.260.0059% mcap17.5% of flowCommon SharesSEC:0001741576-26-000006:3
12,228 shares@ US$235.540.0055% mcap16.4% of flowCommon SharesSEC:0001741576-26-000006:1
3,115 shares@ US$234.550.0014% mcap4.2% of flowCommon SharesSEC:0001741576-26-000006:0
13,685 shares@ US$236.580.0062% mcap18.4% of flowCommon SharesSEC:0001741576-26-000006:2
21,407 shares@ US$234.560.0096% mcap9.0% of flowCommon SharesSEC:0001687858-26-000003:0
29,915 shares@ US$235.510.014% mcap12.6% of flowCommon SharesSEC:0001687858-26-000003:1
16,208 shares@ US$236.540.0073% mcap6.9% of flowCommon SharesSEC:0001687858-26-000003:2
12,470 shares@ US$237.250.0057% mcap5.3% of flowCommon SharesSEC:0001687858-26-000003:3
6,206 shares@ US$233.220.0028% mcap2.6% of flowCommon SharesSEC:0001687858-26-000003:4
3,457 shares@ US$234.290.0016% mcap1.5% of flowCommon SharesSEC:0001687858-26-000003:5
5,704 shares@ US$235.340.0026% mcap2.4% of flowCommon SharesSEC:0001687858-26-000003:6
6,731 shares@ US$236.460.0031% mcap2.9% of flowCommon SharesSEC:0001687858-26-000003:7
16,187 shares@ US$237.230.0074% mcap6.9% of flowCommon SharesSEC:0001687858-26-000003:8
6,244 shares@ US$237.880.0028% mcap2.7% of flowCommon SharesSEC:0001687858-26-000003:9
3,900 shares@ US$234.640.0018% mcap7.0% of flowCommon SharesSEC:0001771383-26-000003:0
10,246 shares@ US$235.510.0046% mcap18.5% of flowCommon SharesSEC:0001771383-26-000003:1
4,426 shares@ US$236.380.0020% mcap8.0% of flowCommon SharesSEC:0001771383-26-000003:2
10,864 shares@ US$237.310.0049% mcap19.8% of flowCommon SharesSEC:0001771383-26-000003:3
3,100 shares@ US$234.590.0014% mcap5.1% of flowCommon SharesSEC:0001786065-26-000003:0
8,195 shares@ US$235.620.0037% mcap13.4% of flowCommon SharesSEC:0001786065-26-000003:1
10,876 shares@ US$236.500.0049% mcap17.9% of flowCommon SharesSEC:0001786065-26-000003:2
12,829 shares@ US$237.260.0058% mcap21.2% of flowCommon SharesSEC:0001786065-26-000003:3
6,665 shares@ US$235.300.0030% mcap13.0% of flowCommon SharesSEC:0001942639-26-000003:0
25 of 265 declarations
About Cardinal Health Inc
Cardinal Health Inc. is a major U.S. healthcare services and products company listed on the NYSE under ticker CAH, and headquartered in Dublin, Ohio, United States. Founded in 1971, the company has evolved into one of the most important players in the American healthcare supply chain, with a long-standing franchise in pharmaceutical distribution and a broader platform serving hospitals, pharmacies, physician offices, laboratories, ambulatory surgery centers, and patients at home.
Cardinal Health reports two main operating segments. Pharmaceutical and Specialty Solutions is its largest and most strategically important business, centered on the distribution of branded, generic, and specialty pharmaceuticals, along with supporting services for manufacturers and healthcare providers. Global Medical Products and Distribution (GMPD) covers medical products, hospital supplies, and distribution solutions. In addition, the company groups several growth-oriented businesses under “Other,” including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics. This portfolio mix shows a deliberate attempt to complement the low-margin but high-scale distribution core with higher-growth, higher-value healthcare services.
Read moreShow less
From a competitive standpoint, Cardinal Health is one of the key U.S. pharmaceutical distributors, operating in an industry characterized by scale, logistics intensity, and tight margins. Its competitive advantages include national reach, purchasing and fulfillment capabilities, deep customer relationships, and the ability to provide integrated solutions across the healthcare value chain. The company also benefits from exposure to specialty pharmacy, patient support, home delivery, nuclear pharmacy operations, and data/performance solutions, which can support long-term earnings diversification.
Recent developments have been strategically meaningful. In 2025, Cardinal Health announced and then completed the acquisition of Solaris Health, a leading urology MSO, strengthening The Specialty Alliance and expanding its multi-specialty management-services platform. It also completed the acquisition of Advanced Diabetes Supply Group, reinforcing its at-Home Solutions franchise. More recently, management raised its fiscal 2026 outlook and highlighted continued momentum across all five operating segments, alongside ongoing investments in automation, distribution capacity, and network optimization. For international investors, CAH remains a mature but actively transforming U.S. healthcare name, with a balance of defensive distribution exposure and selective growth optionality in specialty and home-based care.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
